1 / 2

* P = .009

A. CD3 + in patients. CD3 + in patients. CD3 + CD8 + in patients. CD3 + CD4 + in patients. B. C. CD4 + CD25 high CD45RO +. CD4 + CD28 + CD45RO +. * P = .009. * P = .001. *. *. % of CD3 + CD4 + T cells. % of CD3 + CD4 + T cells. Supplementary Figure 1

flavio
Download Presentation

* P = .009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A CD3+ in patients CD3+ in patients CD3+CD8+ in patients CD3+CD4+ in patients B C CD4+CD25highCD45RO+ CD4+CD28+CD45RO+ *P = .009 *P = .001 * * % of CD3+CD4+ T cells % of CD3+CD4+ T cells Supplementary Figure 1 Immune reconstitution in patients was monitored over the course of transplant. (A) Recovery of CD3+, CD4+ and CD8+ T lymphocytes in patients (n = 20) post-NST. (B) and (C) show two specific CD4+ subsets, each represented as a percentage of the CD4+ compartment, in patients versus healthy normal controls (n = 20). CD4+CD25highCD45RO+ regulatory T cells (B) markedly decreased between pre-NST and day+30, whereas CD4+CD28+CD45RO+ T cells (C) increased between pre-NST and day+30 and maintained consistently higher levels than normal controls throughout (*denotes significant difference at pre-NST between patients and normal controls; NST, nonmyeloablative blood stem cell transplant).

  2. Late PR day+662 % Donor Chimerism Late PR day+129 Late PR day+101 Days after transplantation Supplementary Figure 2 Chimerism trends in the ten responders (seven with partial response, PR and three with stable disease, SD) shown in relation with DLI infusions (indicated by arrows over the graph). The horizontal bar below each graph represents the post-transplantation timeline for the responder showing critical events including onset of regression (indicated by a triangle), removal of cyclosporin (indicated by an oval), and onset of GVHD (indicated by a diamond). Late response timepoints are also shown (“late PR” in patients 7, 16 and 19).

More Related